Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) said its CEO Dr. Amit Kumar discussed the company’s advancing immunotherapy pipeline on Smart Money Circle on April 6, 2026. Key clinical updates: the breast cancer vaccine completed Phase 1 meeting primary endpoints with protocol-defined immune responses in 74% of participants, and the ovarian CAR-T therapy lira-cel is showing positive survival data in an ongoing Phase 1 trial.
The interview highlights clinical progress across both programs and ongoing development work for potential next steps.
AI-generated analysis. Not financial advice.
Positive
- Breast vaccine Phase 1 met primary endpoints with 74% immune responses
- Ovarian CAR-T lira-cel reporting positive survival data in ongoing Phase 1
Negative
- Both programs remain in Phase 1, indicating early-stage clinical risk
- No pivotal or late-stage efficacy or regulatory approvals reported to date
News Market Reaction – ANIX
On the day this news was published, ANIX gained 1.57%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While ANIX was down 6.25%, all listed biotech peers (e.g., STTK +5.77%, PYXS +3.5%) traded higher, pointing to stock-specific pressure rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | Breast vaccine results | Positive | +5.4% | Final Phase 1 breast cancer vaccine data and Phase 2 manufacturing plans. |
| Mar 30 | CAR-T trial update | Positive | -2.0% | Announcement of upcoming ovarian cancer CAR-T trial presentation at SGO meeting. |
| Mar 12 | Investor podcast | Positive | -2.7% | CEO podcast discussing positive clinical data and company plans and finances. |
| Mar 09 | Patent allowance | Positive | +4.6% | Korean patent allowance expanding IP for breast cancer vaccine technology. |
| Mar 02 | Annual meeting notice | Positive | -0.7% | Annual meeting announcement with clinical and regulatory pipeline highlights. |
Positive clinical and corporate news has often seen mixed or negative next-day price reactions.
Over the past month, ANIX has repeatedly highlighted progress in its breast cancer vaccine and ovarian cancer CAR-T programs. Events include positive final Phase 1 vaccine data, expanded IP protection in Korea, and preparations for Phase 2, alongside presentations and podcasts discussing encouraging clinical results. Price reactions have been inconsistent: strong gains followed some updates, while others, including positive trial communications and corporate events, saw modest declines. Today’s interview-focused news fits this pattern of upbeat developments against uneven share performance.
Regulatory & Risk Context
An active Form S-3 shelf filed on 2025-09-10 and expiring on 2028-09-10 allows Anixa to issue various securities, but it has 0 recorded usages so far and is not yet effective according to the provided data.
Market Pulse Summary
This announcement reinforces prior disclosures that Anixa’s breast cancer vaccine met Phase 1 endpoints with protocol-defined immune responses in 74% of participants and that its ovarian cancer CAR-T program has shown encouraging survival trends. The interview format extends the company’s outreach rather than adding new data. Investors may monitor upcoming Phase 2 planning, further CAR-T survival updates, cash trends around the reported $14.202M balance, and any use of the existing Form S-3 shelf or at-the-market facility.
Key Terms
car-t therapy medical
phase 1 clinical trial medical
immunotherapy medical
primary endpoints medical
protocol-defined immune responses medical
AI-generated analysis. Not financial advice.
During the interview, Dr. Kumar discussed Anixa's innovative approach to cancer treatment and prevention, with a particular focus on the Company's advancing immunotherapy pipeline, including its breast cancer vaccine and ovarian cancer CAR-T therapy programs. Anixa's breast cancer vaccine recently completed a Phase 1 clinical trial where it met primary endpoints and generated protocol-defined immune responses in
The full interview is available here: Smart Money Circle Interview.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-ceo-featured-on-smart-money-circle-interview-highlighting-advances-in-cancer-immunotherapy-programs-302734195.html
SOURCE Anixa Biosciences, Inc.